CANBRIDGE PHARMACEUTICALS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.33 HKD | 0.00% |
|
-8.33% | -66.67% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -66.67% | 17.95M | - | ||
| +7.95% | 72.21B | A | ||
| +15.70% | 9.14B | A- | ||
| -24.60% | 4.33B | A- | ||
| +15.26% | 4.28B | B- | ||
| +28.46% | 4.15B | - | ||
| +7.76% | 2.19B | B | ||
| -35.98% | 1.98B | C- | ||
| +7.76% | 1.98B | - | - | |
| -47.71% | 1.68B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-
- Stock Market
- Equities
- 1228 Stock
- Ratings CANbridge Pharmaceuticals Inc.
